Gut microbiota elicits a protective immune response against malaria transmission

Bahtiyar Yilmaz,Silvia Portugal,Tuan M Tran,Raffaella Gozzelino,Susana Ramos,Joana Gomes,Ana Regalado,Peter J Cowan,Anthony J F d'Apice,Anita S Chong,Ogobara K Doumbo,Boubacar Traore,Peter D Crompton,Henrique Silveira,Miguel P Soares

DOI: https://doi.org/10.1016/j.cell.2014.10.053

IF: 64.5

2014-12-04

Cell

Abstract:Glycosylation processes are under high natural selection pressure, presumably because these can modulate resistance to infection. Here, we asked whether inactivation of the UDP-galactose:β-galactoside-α1-3-galactosyltransferase (α1,3GT) gene, which ablated the expression of the Galα1-3Galβ1-4GlcNAc-R (α-gal) glycan and allowed for the production of anti-α-gal antibodies (Abs) in humans, confers protection against Plasmodium spp. infection, the causative agent of malaria and a major driving force in human evolution. We demonstrate that both Plasmodium spp. and the human gut pathobiont E. coli O86:B7 express α-gal and that anti-α-gal Abs are associated with protection against malaria transmission in humans as well as in α1,3GT-deficient mice, which produce protective anti-α-gal Abs when colonized by E. coli O86:B7. Anti-α-gal Abs target Plasmodium sporozoites for complement-mediated cytotoxicity in the skin, immediately after inoculation by Anopheles mosquitoes. Vaccination against α-gal confers sterile protection against malaria in mice, suggesting that a similar approach may reduce malaria transmission in humans.